THE LACTIgA PLATFORM.

Lactiga is advancing the development of secretory IgA (sIgA)-based biologics based on its essential role in mucosal immune defense. sIgA binds to pathogens, preventing their attachment to epithelial cells, neutralizes toxins, and regulates the microbiota by selectively binding to and controlling specific microbial populations. By reducing pro-inflammatory cytokines, sIgA modulates the immune response and supports immune homeostasis.

Lactiga’s therapeutic approach is designed to treat immune deficiencies and other conditions characterized by compromised mucosal immunity. With significant progress in research and development, Lactiga is positioned to advance these biologics into clinical evaluation and commercialization.

TRANSFORMING TREATMENT ACROSS DISEASE STATES

  • LCTG-001 is a targeted, local, non-systemic intranasal product intended to replace secretory IgA (sIgA) at the mucosal surface in patients with primary humoral immunodeficiencies, including CVID, sIgAD, and XLA. Replacement of sIgA in the upper respiratory tract is intended to restore mucosal immune function, reduce frequency of respiratory infections, and limit progression of pulmonary complications.

  • LCTG-003 is an oral, encapsulated, non-systemic product intended to replace secretory IgA (sIgA) in patients with inflammatory bowel disease (IBD). Dysregulated mucosal immune function in these conditions is associated with impaired sIgA-mediated immune exclusion and loss of tolerance to luminal antigens, including microbial, dietary, and environmental components. Replacement of sIgA is intended to re-establish barrier integrity, modulate antigen sampling at the epithelial interface, and normalize local immune responses to reduce inflammation and disease-related complications.

  • Lactiga’s secretory IgA (sIgA) therapy strengthens the body's defenses where it matters most — the respiratory tract. By delivering protective antibodies directly to the airways, our sIgA therapy can help prevent infections and reduce inflammation in conditions like non-CF bronchiectasis, COPD, and chronic lung allograft dysfunction (CLAD), offering a new layer of protection for people with chronic lung diseases.